Aclaris Therapeutics, Inc. (ACRS) Analysts See $-0.99 EPS; Expedia (EXPE) Sentiment Is 1.06

May 1, 2018 - By Stephen Andrade

Expedia Group, Inc. (NASDAQ:EXPE) Logo

Expedia Inc (EXPE) investors sentiment decreased to 1.06 in 2017 Q4. It’s down -0.37, from 1.43 in 2017Q3. The ratio worsened, as 257 hedge funds opened new and increased equity positions, while 242 reduced and sold holdings in Expedia Inc. The hedge funds in our database now have: 118.55 million shares, down from 124.65 million shares in 2017Q3. Also, the number of hedge funds holding Expedia Inc in top ten equity positions decreased from 20 to 18 for a decrease of 2. Sold All: 80 Reduced: 162 Increased: 172 New Position: 85.

Analysts expect Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to report $-0.99 EPS on May, 8.They anticipate $0.51 EPS change or 106.25% from last quarter’s $-0.48 EPS. After having $-0.80 EPS previously, Aclaris Therapeutics, Inc.’s analysts see 23.75% EPS growth. The stock decreased 1.83% or $0.33 during the last trading session, reaching $17.75. About 153,258 shares traded. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has declined 45.27% since May 1, 2017 and is downtrending. It has underperformed by 56.82% the S&P500.

Among 6 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Aclaris Therapeutics had 14 analyst reports since November 2, 2015 according to SRatingsIntel. The stock of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has “Outperform” rating given on Tuesday, November 29 by Leerink Swann. The stock of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has “Buy” rating given on Wednesday, August 9 by Cantor Fitzgerald. William Blair initiated the shares of ACRS in report on Monday, November 2 with “Outperform” rating. The stock of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has “Buy” rating given on Monday, June 26 by Jefferies. JMP Securities initiated the stock with “Market Perform” rating in Friday, September 30 report. The stock has “Buy” rating by Guggenheim on Friday, June 10. The rating was initiated by Citigroup with “Buy” on Monday, November 2. The firm has “Buy” rating by Jefferies given on Monday, September 19. The rating was maintained by Jefferies with “Buy” on Thursday, August 31. The stock of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has “Buy” rating given on Tuesday, November 7 by Cantor Fitzgerald.

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. The company has market cap of $548.58 million. The Company’s lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis , a common non-malignant skin tumor. It currently has negative earnings. The firm is also developing A-101 as a prescription treatment for common warts.

Expedia, Inc., together with its subsidiaries, operates as an online travel firm in the United States and internationally. The company has market cap of $17.31 billion. The firm operates through four divisions: Core OTA, Trivago, Egencia, and HomeAway. It has a 47.58 P/E ratio. It facilitates the booking of hotel rooms, airline seats, car rentals, and destination services from its travel suppliers; and acts as an agent in the transactions.

The stock increased 0.06% or $0.07 during the last trading session, reaching $115.14. About 2.04M shares traded. Expedia Group, Inc. (EXPE) has declined 17.38% since May 1, 2017 and is downtrending. It has underperformed by 28.93% the S&P500.

Expedia Group, Inc. (NASDAQ:EXPE) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>